BiomX Inc. (PHGE)
NYSEAMERICAN: PHGE · Real-Time Price · USD
0.3965
+0.0070 (1.80%)
Aug 1, 2025, 4:00 PM - Market closed
Instructure Holdings Employees
As of December 31, 2024, BiomX had 57 total employees, including 52 full-time and 5 part-time employees. The number of employees decreased by 14 or -19.72% compared to the previous year.
Employees
57
Change (1Y)
-14
Growth (1Y)
-19.72%
Revenue / Employee
n/a
Profits / Employee
-$141,386
Market Cap
10.38M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 57 | -14 | -19.72% |
Dec 31, 2023 | 71 | 6 | 9.23% |
Dec 31, 2022 | 65 | -54 | -45.38% |
Dec 31, 2021 | 119 | 13 | 12.26% |
Dec 31, 2020 | 106 | 20 | 23.26% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PHGE News
- 19 days ago - BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis - GlobeNewsWire
- 25 days ago - BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis - GlobeNewsWire
- 2 months ago - BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference - GlobeNewsWire
- 2 months ago - BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 2 months ago - BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates - GlobeNewsWire
- 3 months ago - BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025 - GlobeNewsWire
- 4 months ago - BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure - GlobeNewsWire
- 4 months ago - BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) - GlobeNewsWire